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Abstract A kinetic analysis was performed for the novel 1-(8-
phosphonooctyl)-6-amino-5-bromouracil and 1-(8-phosphonooc-
tyl)-7-deazaxanthine inhibitors of Escherichia coli thymidine
(dThd) phosphorylase (TPase). The structure of the compounds
was rationally designed based on the available crystal structure
coordinates of bacterial TPase. These inhibitors reversibly
inhibited TPase. Kinetic analysis revealed that the compounds
inhibited TPase in a purely competitive or mixed fashion not only
when dThd, but also when inorganic phosphate (Pi), was used as
the variable substrate. In contrast, the free bases 6-amino-5-
bromouracil and 7-deazaxanthine behaved as non-competitive
inhibitors of the enzyme in the presence of variable Pi
concentrations while being competitive or mixed with respect to
thymine as the natural substrate. Our kinetic data thus revealed
that the novel 1-(8-phosphonooctyl)pyrimidine/purine derivatives
are able to function as multisubstrate inhibitors of TPase,
interfering at two different sites (dThd(Thy)- and phosphate-
binding site) of the enzyme. To our knowledge, the described
compounds represent the first type of such multisubstrate
analogue inhibitors of TPase; they should be considered as lead
compounds for the development of mechanistically novel type of
TPase inhibitors. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Thymidine phosphorylase (TPase) is one of the key enzymes
involved in salvage biosynthesis and catabolism of pyrimidine
2P-deoxyribonucleosides. It recognises 2P-deoxythymidine
(dThd) and 2P-deoxyuridine (dUrd) as a natural substrate
[1]. TPase functions as a dimer of two identical subunits
with a dimer molecular mass ranging from 90 kDa (Escheri-
chia coli) to 110 kDa (mammals) and catalyses the reversible
phosphorolysis of dThd (and other pyrimidine 2P-deoxyribo-
side analogues) [1] :
pyrimidine 20 ÿ deoxyriboside phosphateI
2ÿ deoxyriboseÿ 1ÿ phosphate pyrimidine
TPase also has deoxyribosyl transferase activity between dif-
ferent pyrimidine bases [1]:
pyrimidine 20 ÿ deoxyribose pyrimidineIpyrimidine
pyrimidine 20 ÿ deoxyribose
The structure of human TPase has not yet been determined.
However, structural determinations have been reported for
two bacterial homologues: E. coli [2,3] and Bacillus stearo-
thermophilus [4], the latter to a higher resolution. These en-
zymes have 40% sequence identity with human TPase. Very
recently, a model for human TPase has been built based on
the crystal structure of E. coli TPase, suggesting almost no
di¡erences in the main tertiary structure. The TPase structures
have revealed that each subunit contains a large mixed K/L
domain separated from a smaller K-helical domain by a cleft
which contains the substrate-binding sites. In the phosphoro-
lytic reaction, it is suggested that the phosphate binds ¢rst to
the K/L domain leading to a structural rearrangement and a
partial closing of the cleft. Subsequent binding of the pyrim-
idine 2P-deoxyriboside causes the cleft to close, excluding
water and leading to the phosphorolytic event, before re-
opening with the pyrimidine bound to the K-helical domain.
Release of the pyrimidine could then be followed either by
binding of another pyrimidine (leading to transferase activity)
or by release of the 2-deoxyribose-1-phosphate [5]. The dis-
tance between the phosphate-binding site and the Thy/dThd-
binding site is estimated to be V10 Aî in the open protein
(Fig. 1).
Interest in TPase has markedly increased in the light of
several recent ¢ndings (reviewed in [6^8]). Firstly, TPase ex-
pression is reported to be inducible by interferon and other
cytokines [7]. Secondly, platelet-derived endothelial cell
growth factor has been shown to be identical to human TPase
[9^12]. Thus, TPase possesses angiogenic and endothelial cell
chemotactic activities. Thirdly, gliostatin, which causes inhibi-
tion of glial cell growth and subsequent stimulation of neuro-
nal outgrowth, has also been shown to be identical to TPase
[7]. The mode of action of TPase as a growth factor is
presently not fully understood, although it has been suggested
that the responsible agent is 2-deoxyribose, derived from
the 2-deoxyribose-1-phosphate released in the TPase reaction
[8].
Few inhibitors of TPase have been reported, most of them
being uracil derivatives such as 6-amino-5-bromouracil
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(6A5BU) (Fig. 2) and 6-aminothymine, albeit with IC50 values
in the sub-micromolar range [13]. Very recently, 5-chloro-6-[1-
(2-iminopyrrolidin)methyl]uracil has been described as a novel
powerful inhibitor with an IC50 value of 33 nM [14]. In our
initial attempt to identify new inhibitors of TPase, molecular
modeling was performed based on the medium resolution of
the E. coli TPase structure. Synthesis and resolution of several
structures derived from our modeling led to the identi¢cation
of 7-deazaxanthine as the ¢rst purine derivative able to inhibit
TPase [15]. In a further step, and again based on the available
E. coli coordinates, several series of compounds were designed
and synthesised, in an attempt to interact simultaneously with
both the phosphate and the pyrimidine-binding site. From
these investigations, the most potent inhibitors proved to be
the 1-(8-phosphonooctyl) derivatives of 6A5BU and 7-deazax-
anthine [16]. Here, we report a detailed kinetic analysis of the
interaction of these novel compounds with bacterial TPase
and demonstrate that they indeed interfere with the two di¡er-
ent sites of the enzyme. To the best of our knowledge they
represent the ¢rst example of multisubstrate analogue inhib-
itors of TPase.
2. Materials and methods
2.l. Molecular modeling procedures
The full-atom model of E. coli TPase was kindly provided by Dr. S.
Ealick (Cornell University, NY, USA) and the inhibitors 6A5BU and
6-aminothymine were modeled into the active site based on the posi-
tion of thymine (Thy) inferred by Walter et al. [15]. The position of
the phosphate-binding site was inferred from the position of a bound
sulphate ion in the crystal structure (a result of the crystallisation
conditions). The rationale behind the design of 7-deazaxanthine has
been described [15]. Phosphonates were considered to be good ana-
logues for the phosphate ion, leaving the choice of linker to be made.
Several types of linkers were considered, as described in [16], with
their lengths and positions of functional groups/unsaturated bonds
being determined by manual model building between the base and
phosphate positions. The goal of the model building was to identify
ways of reducing the £exibility of the linker region (to reduce the
entropic penalty of binding the groups at either end of the linker)
and to attempt to form additional favourable linker^protein interac-
tions (particularly with residue His85).
2.2. Compounds
The synthesis of 7-deazaxanthine was performed according to West
et al. [17]. Thymidine (dThd) and Thy, and E. coli TPase (1030 U/ml)
were obtained from Sigma (St. Louis, MO, USA). 6A5BU was syn-
thesised according to Schroeder [18]. The synthesis of the 1-(8-phos-
phonooctyl) derivative of 6A5BU (TP-64) and 1-(8-phosphonooctyl)-
7-deazaxanthine (TP-65) has been recently described [16]. The struc-
tural formulae are depicted in Fig. 2.
2.3. TPase enzyme assays
The phosphorolysis of dThd by E. coli TPase was measured by high
performance liquid chromatography (HPLC) analysis. The incubation
mixture (500 Wl) contained 10 mM Tris^HCl (pH 7.6), 1 mM EDTA,
2 mM potassium phosphate (unless otherwise stated in the kinetic
experiments), 150 mM NaCl and 100 WM of dThd in the presence
or absence of 100 WM 2-deoxyribose-K-1-phosphate and 0.025 U
TPase. Incubations were performed at room temperature. At di¡erent
time points (i.e. 0, 20, 40 and 60 min), 100 Wl fractions were with-
drawn, transferred to an Eppendorf tube thermo block, and boiled at
95‡C for 5 min. Thereafter, the samples were rapidly cooled on ice,
and dThd was separated from Thy and quanti¢ed in the samples on a
reverse phase RP-8 column (Merck, Darmstadt, Germany) by HPLC
analysis. The separation of Thy and dThd was performed by a linear
gradient from 5% bu¡er B (10 mM potassium phosphate bu¡er pH
5.5+80% methanol) to 20% bu¡er B. After injection of the samples,
bu¡er B was given for 10 min before the start of the gradient (5 min
from 5 to 20% bu¡er B). The retention times of Thy and dThd were
4.2 and 8.5 min, respectively. UV-based detection of Thy and dThd
was performed at 267 nm.
In the assays where the inhibitory e¡ect of the compounds was
evaluated, a variety of inhibitor concentrations, including 1 mM,
100, 10 and 0 WM (control) were added to the reaction mixture (500
Wl) containing 100 WM of dThd. Aliquots of 100 Wl were withdrawn
from the reaction mixture at several time points, as described above,
heated at 95‡C to inactivate the enzyme, and analysed on HPLC.
To discriminate between reversible and irreversible inhibition of
TPase by the inhibitors, 100 WM 7-deazaxanthine and TP-65 were
exposed to di¡erent TPase concentrations (0.005, 0.004, 0.003,
0.0025, 0.0020, 0.001 and 0.0005 U) in a 100 Wl reaction mixture
and incubated for 30 min at room temperature. Conversion of
dThd to Thy was followed as described above.
In the kinetic assays, where the inhibitory e¡ect of the test com-
pounds was evaluated against TPase at varying inorganic phosphate
(Pi) concentrations, the compounds were tested at concentrations
ranging from 0.5 to 200 WM, in the presence of 2, 5, 10, 25, 50 and
100 mM Pi. The (saturating) dThd concentration was kept ¢xed at
1000 WM. The reaction mixture (100 Wl) was then incubated at room
temperature for 20 min with 0.005 U TPase, after which the tubes
were heated at 95‡C before cooling and analysis by HPLC for dThd
conversion to Thy.
In the kinetic assays, where the inhibitory e¡ect of the test com-
pounds was evaluated against TPase at varying Thy or dThd concen-
trations, the compounds were tested at concentrations ranging from
2 to 200 WM or 0.5 to 200 WM, in the presence of 175, 250, 375, 500,
750 and 1000 WM Thy or 125, 250, 500, 750 and 1000 WM dThd,
respectively. The Pi concentration was kept constant at 25 mM. The
analysis of the Thy-to-dThd conversion was performed as described
above.
The data from the kinetic experiments were ¢tted to standard en-
zyme inhibition models (i.e. competitive, non-competitive, mixed) us-
ing Sigma Plot Version 4.0 and are summarised in Table 1. The best
¢t was judged from the non-reduced M2 values (sum of squared resid-
uals) given by the program and the percentage of errors in the ¢tted
parameters.
3. Results
To enable discrimination between reversible and irreversible
Fig. 1. A ball-and-stick diagram of E. coli dThd kinase [3] with one
of the multisubstrate inhibitors (TP-65) modelled into the active
site. Hydrogen bonding interactions between the 7-deazaxanthyl
moiety and the enzyme and between the phosphonyl moiety and the
enzyme are shown by dotted lines. The distance between the binding
sites in the open form of the enzyme is indicated. Figure was drawn
using BobScript [19].
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inhibition of TPase by 7-deazaxanthine and its phosphonoal-
kyl derivative (TP-65), a ¢xed concentration of 100 WM of the
inhibitors was exposed to duplo-dilutions of TPase. Should
the compounds act as irreversible inhibitors of TPase, equi-
molar concentrations of enzyme and inhibitor would com-
pletely annihilate enzymatic activity and, likewise, lower en-
zyme concentrations will be fully inactivated by the
compounds. Consequently, if enzyme concentration was
graphically plotted in the absissa and enzyme velocity in the
ordinate, the enzyme activity curve (in the presence of the
inhibitor) should follow a parallel line with the enzyme activ-
ity curve of control (without inhibitor). If, however, the en-
zyme inhibition is reversible, both the enzyme activity curve
(in the presence of the inhibitor) and the enzyme activity curve
of control (without inhibitor) would converge to the intersec-
Fig. 2. Structural formulae of the substrate analogue inhibitors
6A5BU and 7-deazaxanthine and the multisubstrate analogue inhibi-
tors TP-64 and TP-65.
Table 1
Kinetic parameters for di¡erent inhibitors and substrates (phosphate, dThd and Thy) according to di¡erent enzyme inhibition models
Substrate and
inhibitor
Km ( þ S.E.M.)
(WM)
Ki ( þ S.E.M.)
(WM)
Kii ( þ S.E.M.)
(WM)
Vmax ( þ S.E.M.)
(nmol/hU1033)
Non-reduced M2 value
Thymidine and 6-amino-5-bromouracil :
Competitive 9437 þ 1742 0.80 þ 0.12 ^ 1718 þ 171 183.2
Mixed 11065 þ 2018 1.4 þ 0.45 1.9 þ 0.19 1875 þ 195 159.1
Non-competitive 11498 þ 1647 1.6 þ 0.16 ^ 1914 þ 162 159.6
Thymidine and 7-deazaxanthine :
Competitive 5199 þ 800 7.7 þ 1.2 ^ 1231 þ 82.4 162.3
Mixed 6353 þ 1017 13 þ 3.6 31 þ 14 1357 þ 104 140.8
Non-competitive 7365 þ 866 19 þ 2.0 ^ 1454 þ 90 147.2
Thymidine and TP-64 :
Competitive 3865 þ 337 142 þ 11 ^ 731 þ 31.3 32.1
Mixed 4209 þ 441 179 þ 33 850 þ 617 763 þ 41 30.2
Non-competitive 5084 þ 434 297 þ 19 ^ 842 þ 40.6 35.2
Thymidine and TP-65 :
Competitive 4500 þ 547 54 þ 4.7 ^ 793 þ 50.6 41.1
Mixed 4499 þ 563 53 þ 4.9 5.7U106 þ 5.1U108 793 þ 52.1 41.1
Non-competitive 6160 þ 857 105 þ 8.5 ^ 9.43 þ 78.9 51.1
Thymine and 6-amino-5-bromouracil :
Competitive 1253 þ 206 2.3 þ 0.35 ^ 642 þ 32.1 93.8
Mixed 1395 þ 250 3.06 þ 0.82 34.7 þ 29.1 665 þ 38.9 90.0
Non-competitive 2084 þ 316 8.7 þ 0.91 ^ 761 þ 48.5 114.0
Thymine and 7-deazaxanthine :
Competitive 1123 þ 94.9 16 þ 1.37 ^ 612 þ 14.8 47.0
Mixed 1234 þ 107 21 þ 3.0 254 þ 120 630 þ 16.6 41.8
Non-competitive 1745 þ 175 62 þ 4.9 ^ 702 þ 27.4 73.2
Thymine and TP-64 :
Competitive 2100 þ 151 312 þ 39.7 ^ 225 þ 6.28 17.0
Mixed 2327 þ 214 476 þ 160 1419 þ 887 235 þ 9.1 15.9
Non-competitive 2541 þ 156 792 þ 84.3 ^ 244 þ 6.9 16.6
Thymine and TP-65 :
Competitive 2074 þ 248 93 þ 10.4 ^ 220 þ 10.3 22.5
Mixed 2335 þ 323 125 þ 30.0 700 þ 477 231 þ 13.4 21.3
Non-competitive 2975 þ 317 251 þ 21.4 ^ 256 þ 13.3 24.2
Phosphate and 6-amino-5-bromouracil :
Competitive 2160 þ 1660 0.035 þ 0.025 ^ 503 þ 46 206
Mixed 4390 þ 380 0.74 þ 0.18 0.78 þ 0.04 588 þ 9.2 32.6
Non-competitive 4440 þ 300 0.77 þ 0.03 ^ 588 þ 8.2 32.6
Phosphate and 7-deazaxanthine
Competitive 653 þ 1068 1.0 þ 1.6 ^ 619 þ 45 280
Mixed 3524 þ 424 49 þ 29 27 þ 1.9 797 þ 16 60.3
Non-competitive 3225 þ 300 29 þ 1.6 ^ 789 þ 14 61.8
Phosphate and TP-64
Competitive 2749 þ 290 35 þ 4.8 ^ 948 þ 11 68
Mixed 2796 þ 338 36 þ 6.0 20U103 þ 69U103 951 þ 15 68
Non-competitive 6974 þ 1060 565 þ 138 ^ 1050 þ 43 191
Phosphate and TP-65
Competitive 3666 þ 502 29 þ 5.9 ^ 1667 þ 29 180
Mixed 4327 þ 563 40 þ 9.6 887 þ 390 1727 þ 37 159
Non-competitive 7222 þ 820 300 þ 57 ^ 1840 þ 55 254
Km is the Michaelis^Menten constant of the enzyme, Ki is the dissociation constant of the enzyme, Kii is the dissociation constant of the en-
zyme^substrate complex, Vmax is the maximum velocity of the enzyme reaction.
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tion (zero) point of the absissa/ordinate graph. As evident
from Fig. 3, the latter situation proved to be the case. Thus,
both compounds (7-deazaxanthine (Fig. 3A) and TP-65 (Fig.
3B)) behaved as reversible inhibitors of the enzyme.
The inhibitory activities (potencies) of the test compounds
against TPase have been previously evaluated in the presence
of 100 WM dThd [16]. The kinetic parameters, including the
nature of inhibition and the Ki values of the inhibitors, have
now been determined in the presence of varying concentra-
tions of inhibitor and dThd (Table 1). 6A5BU emerged as the
most potent inhibitor of TPase with a Ki/Km value around
0.0001, and inhibited the enzyme reaction in a mixed or
non-competitive fashion with respect to dThd as the variable
substrate. Also 7-deazaxanthine showed a mixed mode of in-
hibition that was closer to non-competitive than competitive
as judged from the non-reduced M2 (sum of the squared re-
siduals) values. In contrast, TP-64 and TP-65 were less inhib-
itory than 6A5BU and 7-deazaxanthine, but inhibited the en-
zyme reaction in a mixed or competitive fashion with respect
to dThd (Table 1).
We then examined the nature of the kinetic interaction of
6A5BU, 7-deazaxanthine, TP-64 and TP-65 with TPase with
respect to varying concentrations of Thy. The (saturating) Pi
concentrations were kept constant during the enzyme reac-
tions. As shown in Table 1, a comparison of the non-reduced
M2 values for the di¡erent kinetic models shows that 6A5BU
and 7-deazaxanthine invariably inhibited the enzyme in a
mixed fashion with respect to Thy as the varying substrate.
However, a strong tendency to competitive inhibition was
observed (non-reduced M2 values for mixed inhibition were
much closer to the non-reduced M2 values for competitive in-
hibition than for non-competitive inhibition). Also, the phos-
phonoalkyl derivatives of 6A5BU and 7-deazaxanthine
showed a mixed mode of inhibition, but based on the non-
reduced M2 values, it was di⁄cult to delineate a predominant
tendency to either a competitive or a non-competitive mode of
action. The Ki values (for the best ¢t) were around 3.1, 21,
476 and 125 WM for 6A5BU, 7-deazaxanthine, TP-64, and
TP-65, respectively, resulting in Ki/Km values that ranged
from 0.002 to 0.2. The order and degree of potency of the
di¡erent inhibitors was very similar to that obtained with
dThd as the competing substrate (Table 1).
TP-64 and TP-65 were originally designed to enable a con-
comitant interaction of these types of compounds with both
the Thy/dThd substrate-binding site and the phosphate-bind-
ing site of the enzyme. To assess whether the phosphonoalkyl
derivatives of 6A5BU and 7-deazaxanthine are really interact-
ing at the phosphate-binding site, the phosphonate inhibitors
as well as their free base analogues (6A5BU and 7-deazaxan-
thine) were exposed to the enzyme in the presence of various
Pi concentrations at a ¢xed (high) concentration of dThd. The
mixed or purely competitive model was strongly preferred
over the non-competitive model for both phosphonoalkyl de-
rivatives TP-64 and TP-65 (Ki/Km values of V0.01). In con-
trast, the free base inhibitors 6A5BU and 7-deazaxanthine
behaved as non-competitive inhibitors of the enzyme with
respect to Pi (Ki/Km values: 0.0002 and 0.01, respectively).
Thus, whereas the free base analogues can bind independently
of, and concomitantly with, Pi to the enzyme, binding of the
phosphonoalkyl derivatives of these base analogues proved
mutually exclusive with Pi or changed the substrate a⁄nities
of the enzyme upon binding with the inhibitor.
Taken together, the kinetic data presented in Table 1
strongly suggest that the novel phosphonoalkyl derivatives
of 6A5BU and 7-deazaxanthine may interfere with both the
phosphate- and the Thy/dThd-binding site of the enzyme and,
thus, may be considered as multisubstrate analogue inhibitors
of TPase.
4. Discussion
Almost all known inhibitors of TPase can be described as
uracil derivatives interacting at the Thy/dThd-binding site.
Based on the X-ray coordinates published for the E. coli en-
zyme, we have recently designed and synthesised several series
of compounds that should interact both at the Thy/dThd and
the phosphate-binding site, and thus that should behave as
multisubstrate analogue inhibitors of TPase. From the synthe-
sised compounds, the most potent inhibitors of TPase turned
out to be TP-64 and TP-65 [16]. The kinetics of these com-
pounds and of their corresponding free bases, 6A5BU and 7-
deazaxanthine, against bacterial TPase in the presence of dif-
ferent substrates have now been examined. The results ob-
tained clearly indicate that the phosphonoalkyl derivatives
TP-64 and TP-65 inhibited TPase in a competitive or mixed
fashion with respect to both dThd and Pi as the natural sub-
strates, while 6A5BU and 7-deazaxanthine behaved as non-
competitive inhibitors of the enzyme with respect to phos-
phate. These data convincingly argue for an interference of
TP-64 and TP-65 at both substrate (dThd and Pi)-binding
Fig. 3. Reversible inhibition of TPase by 7-deazaxanthine (A) and
TP-65 (B). A concentration of 100 WM inhibitor was used in the en-
zyme reaction and di¡erent concentrations of the enzyme. dThd was
used as the natural substrate.
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sites of the enzyme, as originally designed. It could have been
expected that such multisubstrate analogue inhibitors would
be more potent inhibitors than their corresponding free bases.
However, the linker region connecting the two substrate ana-
logues in these molecules loses a lot of conformational free-
dom on binding to TPase and the resulting loss of entropy
will a¡ect the potency of these compounds adversely. Less
£exible linkers would thus be advantageous and work is al-
ready underway to develop these new molecules.
The observed kinetic nature of the interaction of the com-
pounds with the enzyme depended on whether Thy or dThd
was used as the natural substrate. The most striking di¡erence
was the (expected) trend to competitive inhibition of 6A5BU
when Thy was used, but (unexpected) trend to non-compet-
itive inhibition when dThd was the variable substrate. We
have currently no explanation for this phenomenon. However,
the conformation of the enzyme active site is likely to be
somewhat di¡erent depending on whether Thy or dThd are
bound. It is assumed that during catalysis a domain move-
ment (closing) must occur to produce an active conformation
allowing the phosphate to contact the anomeric position of
dThd followed by a re-opening that allows the Thy to di¡use
from the enzyme. In this respect, a very recent study shows
discrepancies between the binding mode of dThd, based on
docking programmes (Autodock), and the binding mode of
minimised dThd based on bound Thy in the E. coli TPase
coordinates [6]. The authors of this study concluded that the
E. coli X-ray structure resembles more the enzyme-di¡using
Thy conformation than the enzyme-binding dThd conforma-
tion. Thus, the binding modes of the free base analogues, and
even more of the corresponding phosphonoalkyl derivatives,
may be di¡erent under di¡erent experimental conditions
(varying concentrations of Thy and dThd), resulting in a dif-
ferent mode of interaction with the enzyme. It is imperative to
obtain and analyse enzyme crystals complexed with the novel
multifunctional inhibitors to understand these di¡erences in
the interaction of the enzyme with the inhibitors at the mo-
lecular level.
The described phosphonoalkyl derivatives were designed
based on the open conformation of the enzyme, as shown in
Fig. 1, and the kinetic data presented here con¢rmed that they
are indeed able to interfere both at the dThd and at the
phosphate-binding sites. Only cocrystallisation of TPase with
these phosphonoalkyl derivatives should provide formal proof
that these compounds are indeed able to (reversibly) freeze the
conformation of TPase in an open, inactive form.
Since multisubstrate analogue inhibitors have yielded ex-
tremely potent inhibitors of other enzymes, including purine
nucleoside phosphorylases, we expect that our lead com-
pounds may form the basis for further improvement of their
inhibitory activity against TPase, and may result in the very
¢rst potent multisubstrate inhibitor analogues for TPase. The
availability of such potent and speci¢c TPase inhibitors may
allow investigation of their role in the inhibition of angiogen-
esis and cancer.
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